Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Blood Lipid Profiles in Metastatic Prostate Cancer: A Window into Tumor Metabolism and Response to Enzalutamide March 14, 2026
- Organoids from Routine TUR‑P Samples: A Personalized Platform for Prostate Cancer Therapy Testing March 13, 2026
- Estrogen‑Based Androgen Suppression Plus ARSI in Prostate Cancer: A Phase 2 Quality‑of‑Life Trial March 13, 2026
- GLR2037: A First‑in‑Human AR‑Targeted PROTAC Enters Phase 1 Trials in Advanced Prostate Cancer March 13, 2026

Drug Repurposing Against Metastasis?
/in Drug repurposing, Preclinical Research/by MaxPhase 1 Trial of a Polynucleotide Kinase/Phosphatase (PNKP) Inhibitor
/in Clinical Trial, Not PCa related/by MaxPhase 1 Clinical Trial for ADRX-0405 in Advanced Solid Tumors Including Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 trial for ASP1002, a bispecific antibody
/in Clinical Trial, Metastatic, Phase 1/by MaxRethinking Treatment for mHSPC: Insights from Dr. Karim Fizazi
/in Expert Insights, Observational, Retrospective studies/by MaxRetrospective study: Real-World Effectiveness of Apalutamide in mHSPC
/in Observational, Retrospective studies/by MaxAI Predicting Outcomes in Advanced Prostate Cancer
/in Artificial Intelligence/by MaxPhase 2 Adaptive ADT and Docetaxel Trial for mCSPC
/in Clinical Trial, Metastatic, Phase 2/by Max